Synergy IB Investment

RnH-Bio is a biotechnology company that develops exosome-based products for various healthcare applications.

Eastech is a company that specializes in the research and development of drug substance candidates using 3D structural information analysis.

Larchive monitors import and export supply chains for risk management through its intelligence services.

This is a biotechnology company founded by professor Lee Sung-wook's lab They are working on the development of gene therapy products for liver cancer through the development of gene therapy products. It was selected by the TIPS program and was recognized for excellence in technology.

CK Regeon is a biotechnology company focused on improving human health through the development of innovative drugs. The company specializes in creating small molecules and peptides aimed at treating metabolic disorders, including obesity, diabetes, and non-alcoholic steatohepatitis. Additionally, CK Regeon is dedicated to promoting hair growth and enhancing wound healing, utilizing target-specific compounds that enable medical practitioners to effectively address these health issues.

HUINNO, Inc., founded in 2014 and headquartered in Boston, Massachusetts, develops healthcare devices that monitor vital health data, including blood pressure, heart rate, electrocardiogram (ECG), and blood oxygen saturation levels (SpO2). The company leverages proprietary technologies in wearable devices and artificial intelligence to provide healthcare providers with an effective remote patient monitoring solution aimed at improving the management of chronic cardiac diseases. HUINNO's clinically-tested platform delivers real-time measurements with clinical-grade accuracy and offers an application and cloud-based ecosystem for longitudinal analysis of health trends, medication compliance, and lifestyle habits. This comprehensive approach not only enhances patient care but also aids healthcare professionals in making informed medical decisions while treating conditions such as arrhythmia and hypertension. With additional offices in New York and Seoul, HUINNO is committed to transforming the way clinicians and patients manage chronic health issues.

SnackFever Inc., founded in 2015 and based in Los Angeles, California, specializes in delivering a variety of snacks, candies, drinks, ramen products, and other treats from Korea on a subscription basis in the United States. The company focuses on providing a unique culinary experience by offering monthly deliveries that cater to fans of Korean culture and cuisine. Through its offerings, SnackFever aims to connect with the global Hallyu community, delivering not just food items, but also a sense of enjoyment and cultural engagement.

This is a biotechnology company founded by professor Lee Sung-wook's lab They are working on the development of gene therapy products for liver cancer through the development of gene therapy products. It was selected by the TIPS program and was recognized for excellence in technology.

Enfusion is a developer of mobile and PC games

HUINNO, Inc., founded in 2014 and headquartered in Boston, Massachusetts, develops healthcare devices that monitor vital health data, including blood pressure, heart rate, electrocardiogram (ECG), and blood oxygen saturation levels (SpO2). The company leverages proprietary technologies in wearable devices and artificial intelligence to provide healthcare providers with an effective remote patient monitoring solution aimed at improving the management of chronic cardiac diseases. HUINNO's clinically-tested platform delivers real-time measurements with clinical-grade accuracy and offers an application and cloud-based ecosystem for longitudinal analysis of health trends, medication compliance, and lifestyle habits. This comprehensive approach not only enhances patient care but also aids healthcare professionals in making informed medical decisions while treating conditions such as arrhythmia and hypertension. With additional offices in New York and Seoul, HUINNO is committed to transforming the way clinicians and patients manage chronic health issues.

AptaBio Therapeutics Inc. is a pharmaceutical biotechnology company based in Yongin-Si, South Korea, that specializes in the discovery and development of selective inhibitors targeting the NOX family of enzymes, as well as aptamer-based anti-cancer drugs. The company's product offerings include a range of transfection reagents designed for DNA or RNA delivery into eukaryotic cells. AptaBio is advancing several product candidates aimed at addressing significant health issues, including PX-115 for diabetic nephropathy, APX-1004 for diabetic retinopathy, and APX-311 for non-alcoholic steatohepatitis (NASH). Founded in 2009, AptaBio Therapeutics focuses on creating innovative solutions for complex medical challenges.

Neuroventi specializes in creating customized solutions and therapies for brain development disorders. The company focuses on developing treatments for conditions such as autism spectrum disorder and attention deficit hyperactivity disorder by targeting specific molecular processes. In addition to its therapeutic offerings, Neuroventi provides drug discovery services centered on natural products, aiming to assist medical professionals in effectively treating and preventing various neurological disorders. With a commitment to advancing the understanding and management of brain health, Neuroventi seeks to enhance cognitive function and overall well-being.